{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:45:31Z","timestamp":1789029931607,"version":"build-2803163510"},"reference-count":39,"publisher":"Society of Nuclear Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2024,6,19]]},"published-print":{"date-parts":[[2024,9]]},"DOI":"10.2967\/jnumed.124.267667","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T17:35:32Z","timestamp":1723656932000},"page":"1435-1442","source":"Crossref","is-referenced-by-count":11,"title":["Single Chelator\u2013Minibody Theranostic Agents for<sup>89<\/sup>Zr PET Imaging and<sup>177<\/sup>Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer"],"prefix":"10.2967","volume":"65","author":[{"given":"Khanh-Van","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Tatum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Watkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Carmack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Mascioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Maitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Magda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn J.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"key":"2024090306450636000_65.9.1435.1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4573"},{"key":"2024090306450636000_65.9.1435.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30314-7"},{"key":"2024090306450636000_65.9.1435.3","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.237602"},{"key":"2024090306450636000_65.9.1435.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2024090306450636000_65.9.1435.5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264402"},{"key":"2024090306450636000_65.9.1435.6","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262713"},{"key":"2024090306450636000_65.9.1435.7","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3390\/ph16050692","article-title":"Characterization of non-specific uptake and retention mechanisms of [177Lu]Lu-PSMA-617 in the salivary glands","volume":"16","author":"Heynickx","year":"2023","journal-title":"Pharmaceuticals (Basel)."},{"key":"2024090306450636000_65.9.1435.8","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.3390\/cancers13164023","article-title":"PSMA theranostics: current landscape and future outlook","volume":"13","author":"Zhang","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2024090306450636000_65.9.1435.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.11.013"},{"key":"2024090306450636000_65.9.1435.10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.110.076174"},{"key":"2024090306450636000_65.9.1435.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.176206"},{"key":"2024090306450636000_65.9.1435.12","doi-asserted-by":"crossref","first-page":"848.e9","DOI":"10.1016\/j.urolonc.2020.05.028","article-title":"Phase I trial of docetaxel plus lutetium-177-labeled anti\u2013prostate\u2010specific membrane antigen monoclonal antibody J591 (177Lu\u2010J591) for metastatic castration\u2010resistant prostate cancer","volume":"38","author":"Batra","year":"2020","journal-title":"Urol Oncol."},{"key":"2024090306450636000_65.9.1435.13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1634\/theoncologist.2020-0028","article-title":"Pilot study of hyperfractionated dosing of lutetium\u2010177\u2013labeled antiprostate\u2010specific membrane antigen monoclonal antibody J591 (177Lu\u2010J591) for metastatic castration\u2010resistant prostate cancer","volume":"25","author":"Niaz","year":"2020","journal-title":"Oncologist."},{"key":"2024090306450636000_65.9.1435.14","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1002\/cncr.32072","article-title":"Phase 1\/2 study of fractionated dose lutetium\u2010177\u2013labeled anti\u2013prostate\u2010specific membrane antigen monoclonal antibody J591 (177Lu\u2010J591) for metastatic castration\u2010resistant prostate cancer","volume":"125","author":"Tagawa","year":"2019","journal-title":"Cancer."},{"key":"2024090306450636000_65.9.1435.15","doi-asserted-by":"crossref","unstructured":"Tully KM Nagle VL Korsen JA Lewis JS . Antibody-based molecular imaging. In: Ross BD Gambhir SS , eds. Molecular Imaging. 2nd ed. Elsevier; 2021:547\u2013562.","DOI":"10.1016\/B978-0-12-816386-3.00024-7"},{"key":"2024090306450636000_65.9.1435.16","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1021\/acs.chemrev.8b00294","article-title":"Radioactive main group and rare earth metals for imaging and therapy","volume":"119","author":"Kostelnik","year":"2019","journal-title":"Chem Rev."},{"key":"2024090306450636000_65.9.1435.17","doi-asserted-by":"publisher","DOI":"10.1039\/C3CS60304K"},{"key":"2024090306450636000_65.9.1435.18","doi-asserted-by":"publisher","DOI":"10.1021\/ja983706q"},{"key":"2024090306450636000_65.9.1435.19","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1002\/chem.200400006","article-title":"Complexing mechanism of the lanthanide cations Eu3+, Gd3+, and Tb3+ with 1,4,7,10\u2010tetrakis (carboxymethyl)\u20101,4,7,10\u2010tetraazacyclododecane (dota): characterization of three successive complexing phases\u2014study of the thermodynamic and structural properties of the complexes by potentiometry, luminescence spectroscopy, and EXAFS","volume":"10","author":"Moreau","year":"2004","journal-title":"Chemistry."},{"key":"2024090306450636000_65.9.1435.20","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ica.2018.05.031","article-title":"Examination of lutetium (III)-DOTA and copper (II)-NOTA solution structures using EXAFS","volume":"482","author":"Brown","year":"2018","journal-title":"Inorganica Chim Acta."},{"key":"2024090306450636000_65.9.1435.21","doi-asserted-by":"publisher","DOI":"10.1021\/mp500164r"},{"key":"2024090306450636000_65.9.1435.22","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262485"},{"key":"2024090306450636000_65.9.1435.23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1316922111"},{"key":"2024090306450636000_65.9.1435.24","doi-asserted-by":"crossref","first-page":"103571","DOI":"10.1016\/j.ebiom.2021.103571","article-title":"Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumour-infiltrating immune cells in glioma","volume":"71","author":"Foster","year":"2021","journal-title":"EBioMedicine."},{"key":"2024090306450636000_65.9.1435.25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.nucmedbio.2021.12.003","article-title":"Radiolabeling of PSMA-617 with 89Zr: a novel use of DMSO to improve radiochemical yield and preliminary small-animal PET results","volume":"106\u2013107","author":"Imura","year":"2022","journal-title":"Nucl Med Biol."},{"key":"2024090306450636000_65.9.1435.26","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.216457"},{"key":"2024090306450636000_65.9.1435.27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264979"},{"key":"2024090306450636000_65.9.1435.28","unstructured":"Tatum D Xu J Magda D Butlin N , inventors; Lumiphore Inc., assignee. Macrocyclic ligands with pendant chelating moieties and complexes thereof. U.S. patent US10239878B2. March 26, 2019."},{"key":"2024090306450636000_65.9.1435.29","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1021\/mp5006917","article-title":"Evaluation of 68Ga-and 177Lu-DOTA-PEG4-LLP2A for VLA-4-targeted PET imaging and treatment of metastatic melanoma","volume":"12","author":"Beaino","year":"2015","journal-title":"Mol Pharm."},{"key":"2024090306450636000_65.9.1435.30","doi-asserted-by":"publisher","DOI":"10.7150\/thno.13624"},{"key":"2024090306450636000_65.9.1435.31","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264225"},{"key":"2024090306450636000_65.9.1435.32","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264230"},{"key":"2024090306450636000_65.9.1435.33","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1039\/D0MD00319K","article-title":"Formulation and clinical translation of [177Lu]Lu-trastuzumab for radioimmunotheranostics of metastatic breast cancer","volume":"12","author":"Guleria","year":"2020","journal-title":"RSC Med Chem."},{"key":"2024090306450636000_65.9.1435.34","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1007\/s11307-020-01518-4","article-title":"Evaluation of [131I]I-and [177Lu]Lu-DTPA-A11 minibody for radioimmunotherapy in a preclinical model of PSCA-expressing prostate cancer","volume":"22","author":"Tsai","year":"2020","journal-title":"Mol Imaging Biol."},{"key":"2024090306450636000_65.9.1435.35","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.147413"},{"key":"2024090306450636000_65.9.1435.36","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265433"},{"key":"2024090306450636000_65.9.1435.37","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.250738"},{"key":"2024090306450636000_65.9.1435.38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3390\/biom11020263","article-title":"177Lu-PSMA-617 therapy in mice, with or without the antioxidant \u03b11-microglobulin (A1M), including kidney damage assessment using 99mTc-MAG3 imaging","volume":"11","author":"Kristiansson","year":"2021","journal-title":"Biomolecules."},{"key":"2024090306450636000_65.9.1435.39","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219352"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.267667","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T13:48:55Z","timestamp":1725371335000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.267667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":39,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,3]]},"published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.2967\/jnumed.124.267667"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.267667","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,14]]}}}